Exercise of Share Options and Total Voting Rights
Summary by AI BETAClose X
5 May 2026
Tristel plc
("Tristel" or the "Company")
Exercise of Share Options and Total Voting Rights
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has issued and allotted a total of 20,000 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of options by employees of the Company.
Application has been made to the London Stock Exchange for the 20,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 11 May 2026.
Total Voting Rights
After Admission, the total number of Ordinary Shares in issue will be 47,951,543 and the total number of voting rights will therefore be 47,951,543. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact:
|
Tristel plc |
Via Walbrook PR |
|||
|
Matt Sassone, Chief Executive Officer |
||||
|
Anna Wasyl, Chief Financial Officer |
|
|||
|
|
|
|||
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or tristel@walbrookpr.com |
|||
|
Paul McManus / Lianne Applegarth / Anna Dunphy |
Mob: 07980 541 893/ 07584 391 303/ 07876 741 001 |
|||
|
|
|
|||
|
Cavendish Capital Markets Ltd |
Tel: 020 7220 0500 |
|||
|
Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance) |
|
|||
|
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales) |
|
|||
About Tristel plc
Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, which also encompasses its sporicidal surface disinfection range offered as a sustainable alternative to commonly used pre‑wetted plastic wipe.
Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation.
The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product range please visit: https://tristel.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 23 hours ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund